Stockwinners Market Radar for November 03, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:14 EDT Kirkland Lake Gold reports Q3 gold production 370.1K oz, up 9% y/y - Targets top half of production guidance of 1.3M-1.4M oz

18:53 EDT Big 5 Sporting reports Q3 SSS down 0.7%

18:51 EDT Big 5 Sporting declares $1.00 special dividend - The dividend is payable on December 1, 2021, to stockholders of record as of November 17, 2021.

18:35 EDT Wingstop CEO: Wing prices are coming down - In an interview on CNBC's Mad Money, Charlie Morrison said the supply of chicken wings is growing and it's creating optimism. "It's a great time to be building restaurants," he added. The company's International business is "booming" according to Morrison. The strength of the brand and advertising continues, he noted. The company is seeing labor cost inflation, but expects to manage through it.

18:23 EDT NiSource CEO: Well down the path to 90% reduction in GHG emissions by 2030 - Joe Hamrock is speaking on an interview on CNBC's Mad Money.

17:48 EDT Monomoy Capital to acquire Trinity Highway Products for $375M - Monomoy Capital Partners announced that it has signed a definitive agreement to acquire Trinity Highway Products from Trinity Industries for approximately $375M. The transaction remains subject to customary closing conditions and regulatory approval. Founded in 1973, THP is a manufacturer and lessor of highway safety products, including crash cushions, end terminals, guardrails and truck-mounted attenuators. Trinity operates 14 manufacturing and rental distribution facilities in the United States and maintains sales offices in Europe, South America and Asia. President Nick Verska will continue to lead THP as chief executive officer of the business from THP's corporate headquarters in Dallas, Texas.

17:34 EDT Lannett announces restructuring plan, workforce reduction of 11% - In light of the accelerated declines in the base business, the company also announced a restructuring plan approved by the board earlier this week. The restructuring retains core strategies, while further optimizing operations, improving efficiencies and reducing costs. Elements of the plan, which is expected to be completed in about 18 months, include: consolidating the manufacturing footprint; transferring liquid drug production to the company's main plant in Seymour, Indiana from its facility in Carmel, New York; closing the Carmel plant and pursuing its sale; restructuring the R&D function; reducing headcount and discontinuing future development programs targeting liquid generic medications; raising threshold requirements for other internally developed products and starting projects earlier, resulting in fewer but potentially larger market opportunity products; further product rationalization, over time, as the company has done in the past. This particular exercise primarily involves scaling back or phasing out some low margin OTC products, made at the Carmel site, and two very low margin prescription products. Overall, the current organizational workforce will be reduced by approximately 11%, and other existing and anticipated future vacancies will not be filled. Ultimately, the plan is expected to result in a leaner, more focused organization and generate cost savings of approximately $20M, annually.

17:19 EDT Electronic Arts says EA Sports 'well head' of expectations for FY21 - Says has built a "powerful" native mobile organization within EA after recent acquisitions. Says "FIFA Ultimate Team" sales are up year-over-year. Says EA Sports "well ahead" of expectations for the year. Says expectations for "Battlefield 2042" unchanged from last call despite delay.

17:14 EDT Gladstone Commercial announces $12.8M industrial acquisition in NC - Gladstone Commercial acquired a 161,458 square foot industrial facility on 20.45 acres in Monroe, North Carolina for $12.8 million on November 3.The property is Gladstone Commercial's third industrial acquisition in the Charlotte, North Carolina MSA. The property is 100% leased to Assa Abloy Entrance Systems, U.S. with 7.9 years of remaining absolute NNN lease term. The property serves as Assa Abloy's North American headquarters and is utilized for manufacturing and distribution of its access/entrance products and solutions. The acquisition of the industrial property is consistent with Gladstone Commercial's growth strategy of acquiring functional assets, leased to credit-worthy tenants in strong industrial locations. "We are excited to continue building our industrial presence in the Southeast. This facility is the North American headquarters for a strong tenant, and we are pleased to add another Charlotte-area property to the portfolio," stated EJ Wislar, Senior Vice President of Gladstone Commercial.

17:11 EDT Electronic Arts says 'Apex Legends' continues to grow user base - Says "FIFA 22" off to strongest start in franchise history. Says more confident than ever in "bright" future of soccer games. Says engagement in "Madden NFL 22" has grown each week of the NFL season. Says has grown "F1" game business with release of "F1 2022." Comments taken from Q2 earnings conference call

17:08 EDT Ranger Oil sees Q4 reported oil sales volumes 25,700-27,700 bbl/d

17:04 EDT Huntington Ingalls increases quarterly dividend to $1.18 per share - Huntington Ingalls announced that its board of directors has declared a quarterly cash dividend of $1.18 per share, a 4c increase over the $1.14 per share dividend paid in each of the prior four quarters. The $1.18 per share dividend will be payable on December 10, to shareholders of record as of the close of business on November 26.

17:03 EDT MKS Instruments to acquire Atotech - The board of directors of Atotech Limited (ATC) and the board of directors of MKS Instruments (MKSI) announced that they had entered into a definitive agreement pursuant to which MKS would acquire the entire issued and to be issued share capital of Atotech. The deal is expected to become effective in Q4 of 2021.

16:58 EDT Lone Star Funds affiliate acquires five hotels from Host for $551M - Lone Star Funds announced that a Lone Star affiliate has acquired five luxury and upper upscale hotels from Host Hotels & Resorts, Inc. for an aggregate purchase price of $551M, including approximately $11M for furniture, fixtures, and equipment replacement funds. The hotels are: The Whitley, A Luxury Collection Hotel, Atlanta Buckhead in Georgia; The Westin Buckhead Atlanta in Georgia; The Westin Los Angeles Airport, located at the Los Angeles International Airport in California; San Ramon Marriott, located in Santa Clara, California; and the Westfields Marriott Washington Dulles, located in Chantilly, Virginia.

16:58 EDT iBio acquires FastPharming manufacturing facility - iBio, Inc. announced it has purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital Limited. The company also acquired the approximate 30% equity interest in iBio CDMO, LLC. held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are now wholly-owned by iBio, it said in a statement. Before fees and settlement costs, the cost of the transaction was $28,750,000, comprised of $28,000,000 in cash plus warrants to purchase 1,000,000 shares of iBio common stock. iBio issued additional warrants to purchase 289,581 shares of common stock to pay for the final rent due. The total warrants to purchase 1,289,581 shares of common stock are immediately exercisable, will expire on October 10, 2026, and have an exercise price of $1.33 per share. iBio provided approximately $6,000,000 in capital to fund the purchase. To fund the remaining cash portion of the transaction, iBio entered into a $22,375,000 Senior Secured Term Loan with Woodforest National Bank.

16:53 EDT APA Corp. commits to return minimum of 60% of FCF to shareholders - APA is committing to return a minimum of 60% of Free Cash Flow to shareholders through dividends and stock repurchases.

16:53 EDT Ampco-Pittsburgh subsidiaries to boost price on forged, cast rolls - Ampco-Pittsburgh Corporation announced that its subsidiary, Union Electric Steel Corporation, will raise prices on forged and cast roll products that it and its subsidiaries produce globally. This increase is effective immediately on all orders. The price adjustments are driven by continued upward pricing pressures on the cost of raw materials, natural gas, electricity, transportation, labor, and other consumables, increasing production costs due to growing product demand, and other global supply chain factors. Consequently, Union Electric Steel will increase its pricing levels on forged and cast rolls products by 8-12%, depending on contractual energy surcharge coverages currently in place. Commenting on the announcement, Skip Reinert, Vice President of Sales and Marketing, stated, "As the overall metal industry has ramped activity, manufacturing and supply chain costs, including natural gas, labor, and transportation, continue to increase dramatically. Additionally, our business continues to be impacted by the increasing costs of key raw materials. This price adjustment is necessary to maintain a reliable supply of superior-quality products for our customers."

16:47 EDT PDC Energy: Planned level of operating activity through 2023 unchanged - The company said: "The Company's planned levels of operating activity through 2023 remain generally unchanged. Assuming the aforementioned fourth quarter 2021 pricing and mid-cycle commodity pricing, below current strip, of $65 and $60 per Bbl WTI in 2022 and 2023, respectively, and $3.00 per Mcf NYMEX natural gas and $17.50 NGL realizations in each 2022 and 2023, PDC expects to generate more than $2.5 billion of after-tax FCF from 2021 through 2023. The Company is aiming to reduce total debt by $1 billion and return at least $1 billion to shareholders over the three-year timeframe."

16:44 EDT Ceridian sees FY21 adjusted EBITDA $156M-$162M - Sees FY21 adjusted EBITDA margin 15.4%-15.9%.

16:41 EDT GMS Inc. to acquire AMES Taping Tools for $212.5M in cash - GMS announced that it has entered into a definitive agreement to acquire AMES Taping Tools Holding LLC. AMES is a provider of automatic taping and finishing tools and related products to the professional drywall finishing industry. The transaction is expected to close in the Company's fiscal third quarter 2022 with a purchase price of $212.5M in cash. "We are pleased to welcome the AMES team to GMS and provide a full suite of offerings for interior contractors and drywall finishers," said John C. Turner, Jr., President and Chief Executive Officer of GMS. "AMES has highly-respected brands and an entrepreneurial culture with an attractive growth plan, which all align well with our strategic priorities and provide an excellent opportunity for GMS to expand our presence in the growing ATF tools market. With its multichannel distribution model and strong customer relationships, AMES is expected to generate accretive EBITDA margins for GMS. We believe this transaction will add immediate benefits as part of one of our strategic growth priorities to diversify our core product offerings, and will further position GMS to drive long-term growth and shareholder value." GMS expects to fund this transaction with cash on hand and borrowings under the Company's ABL credit facility. In connection with this transaction, GMS will be exercising the $100 million accordion within the Company's ABL agreement, increasing the ABL borrowing limit from $445 million to $545 million. Following the closing of the transaction, AMES's current management team, including President & CEO Jay Davisson, will continue to lead the business, which will continue to operate under the "AMES" brand - as it has for over 80 years. GMS expects to leverage its existing relationship with AMES and the sourcing arrangements at GMS's subsidiary, Tool Source Warehouse, to expand and enhance AMES's distribution model, better capitalize on available growth opportunities and provide an even higher level of service to customers. This transaction is expected to close in GMS's fiscal third quarter of 2022, subject to the satisfaction of customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

16:38 EDT Zymergen eliminated 220 positions, to focus on fewer programs - Zymergen said it has reviewed potential market opportunities and its related portfolio and "will focus on a smaller number of programs that it believes capitalize on its capabilities and provide clear commercial opportunities." Accordingly, several programs will be discontinued, including: The electronics film programs, with the exception of ZYM0101, which is being developed in partnership with Sumitomo Chemical. "Emerging data on the market segment being targeted with Hyaline and other electronics films indicates a smaller near-term opportunity than previously expected," the company said; The consumer care programs, including insect repellent, ZYM0201. "Based on the portfolio review, the costs of customer acquisition with a direct-to-consumer model were prohibitive and, in the case of ZYM0201, it could not be produced and distributed at a price point competitive with incumbent products," it added. As a result of these changes, the company eliminated approximately 220 positions across a variety of levels and functions. These decisions, along with a reduction in related overhead spending, are expected to slow the company's cash burn rate sufficiently to operate to the middle of 2023 with cash on hand. As part of the portfolio review, two programs in the healthcare market have been promoted: one for development of key enzymes used in vaccine production, and a second in drug discovery. The company "has also continued to see success with its work in agriculture, particularly with a flagship program on nitrogen fixation where it is working with a partner, and is still evaluating other programs that are in early concept stages," it said.

16:37 EDT Blackstone announces formation of Structured Finance Group - Blackstone announced the formation of its Structured Finance Group, which brings together Blackstone Real Estate Debt Strategies and the firm's various asset backed finance activities. Jonathan Pollack, currently the Global Head of BREDS, has been named Global Head of the Structured Finance Group. Timothy Johnson, currently the Global Head of Originations for BREDS, will become Global Head of BREDS, overseeing all commercial and residential lending activities. Rob Camacho will continue to lead the firm's investment activities in asset based finance. Mike Wiebolt, who currently manages the Real Estate Group's liquid securities activities, will now also manage asset backed securities.

16:35 EDT Hyatt sees FY21 CapEx roughly $110M - Adjusted selling, general, and administrative expenses are expected to be approximately $245 million to $250 million, inclusive of approximately $5 million to $10 million of expenses related to non-recurring integration costs for ALG. Refer to the table on page 13 of the schedules for a reconciliation of selling, general, and administrative expenses to Adjusted selling, general, and administrative expenses.

16:30 EDT Curtiss-Wright working to mitigate negative impacts of supply chain disruption

16:28 EDT Corcept Therapeutics provides updates on upcoming milestones - For solid tumors: Phase 3 trial in patients with recurrent platinum-resistant ovarian cancer planned to start in the first quarter of 2022; updated overall survival data from the Phase 2 trial expected in the first quarter of 2022; Selection of the optimum dose of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer expected later this year; Enrollment continues in 20-patient, open-label, Phase 1b trial of relacorilant plus PD-1 checkpoint inhibitor pembrolizumab in patients with adrenal cancer with cortisol excess. For Metabolic Diseases: Initiated Phase 1b dose-finding trial in patients with presumed NASH; results of our Phase 2 study to be presented at the American Association for the Study of Liver Diseases meeting, November 12 - 15; Completion of enrollment in GRATITUDE II, a 150-patient, double-blind, placebo-controlled Phase 2 trial of miricorilant to reverse long-standing AIWG, expected by year-end; Completion of enrollment in GRATITUDE, a 100-patient double-blind, placebo-controlled Phase 2 trial of miricorilant to reverse recent AIWG, expected by mid-2022. For Cushing's Syndrome: Enrollment continues in Phase 3 GRACE trial of relacorilant as a treatment for patients with all etiologies of Cushing's syndrome; new drug application (NDA) submission expected in the second quarter of 2023; Enrollment continues in Phase 3 GRADIENT trial of relacorilant as a treatment for patients with Cushing's syndrome caused by adrenal adenomas

16:24 EDT Brigham Minerals reports Q3 daily production volumes 9,068 Boe/d - Reports Q3 production up 1% sequentially vs. Q2.

16:22 EDT Marathon Oil backs 2021 capital expenditure guidance of $1B - Marathon Oil said its 2021 capital expenditure guidance of $1B remains unchanged, as do the midpoints of full year 2021 total company oil and oil-equivalent production guidance. "Marathon Oil is raising its full year 2021 Equatorial Guinea equity method income guidance for the second consecutive quarter to a new range of $235 million to $255 million. The company's full year 2021 production and Equatorial Guinea equity method income guidance fully contemplate an unplanned outage experienced in Equatorial Guinea late in the third quarter. Normal operations resumed this week. During fourth quarter, Marathon Oil expects total oil production to increase to between 176,000 and 180,000 net bopd in comparison to third quarter production of 168,000 net bopd. The company expects fourth quarter total oil-equivalent production to be similar to third quarter production of 345,000 net boed," it said.

16:22 EDT Pioneer Natural sees FY21 capital budget $3.1B-$3.4B - The Company expects its 2021 drilling, completions and facilities capital budget to range between $2.95 billion to $3.25 billion. An additional $100 million and $50 million is budgeted for integration expenses related to the acquisitions of Parsley and DoublePoint, respectively, resulting in a total 2021 capital budget range of $3.1 billion to $3.4 billion. The Company expects its capital program to be fully funded from forecasted 2021 cash flow of $6.55 billion. During 2021, the Company plans to operate an average of 22 to 24 horizontal drilling rigs in the Permian Basin, including a one-rig average program in the Delaware Basin and a three-rig average program in the southern Midland Basin joint venture area. The 2021 capital program is expected to place approximately 535 wells on production. Pioneer expects 2021 oil production of 356 to 359 MBOPD and total production of 613 to 619 MBOEPD, reflecting the impact of the Glasscock acreage divestiture that closed in October 2021.

16:22 EDT Roku reports Q3 platform revenue up 82% to $583M - Reports Q3: Active Accounts reached 56.4M, up 1.3M from Q2, Streaming hours 18.0B, up 0.7B from Q2, and Average Revenue Per User, ARPU, up 49% y/y to $40.10.

16:21 EDT Southwestern Energy sees FY21 capital budget $3.1B-$3.4B - The Company expects its 2021 drilling, completions and facilities capital budget to range between $2.95 billion to $3.25 billion. An additional $100 million and $50 million is budgeted for integration expenses related to the acquisitions of Parsley and DoublePoint, respectively, resulting in a total 2021 capital budget range of $3.1 billion to $3.4 billion. The Company expects its capital program to be fully funded from forecasted 2021 cash flow of $6.55 billion. During 2021, the Company plans to operate an average of 22 to 24 horizontal drilling rigs in the Permian Basin, including a one-rig average program in the Delaware Basin and a three-rig average program in the southern Midland Basin joint venture area. The 2021 capital program is expected to place approximately 535 wells on production. Pioneer expects 2021 oil production of 356 to 359 MBOPD and total production of 613 to 619 MBOEPD, reflecting the impact of the Glasscock acreage divestiture that closed in October 2021.

16:20 EDT Pioneer Natural sees Q4 oil production 388-403 MBOPD - Fourth quarter 2021 oil production is forecasted to average between 388 to 403 MBOPD and total production is expected to average between 670 to 695 MBOEPD, reflecting the impact of the Glasscock acreage divestiture that closed in October 2021. Production costs are expected to average $7.50 per BOE to $9.00 per BOE, reflecting the impact of higher commodity prices on forecasted production taxes. DD&A expense is expected to average $10.75 per BOE to $12.75 per BOE. Total exploration and abandonment expense is forecasted to be $10 million to $20 million. G&A expense is expected to be $67 million to $77 million. Interest expense is expected to be $39 million to $44 million. Other expense is forecasted to be $15 million to $30 million. Accretion of discount on asset retirement obligations is expected to be $2 million to $5 million. The cash flow impact related to purchases and sales of oil and gas, including firm transportation, is expected to be a loss of $45 million to $75 million, based on forward oil price estimates for the quarter. The Company's effective income tax rate is expected to be between 22% to 27%.

16:16 EDT Americold Realty Trust names George Chappelle as interim CEO - George Chappelle, a former Tyson Foods executive and former Chairman of the Board of AGRO Merchants Group, has been appointed Interim CEO, effective immediately. Chappelle's appointment follows the decision of the Americold Board of Trustees to terminate Fred Boehler without cause. Boehler also resigned as a Trustee. The Americold Board has engaged a nationally recognized search firm to identify a permanent CEO, it said. The company noted that Mr. Boehler's departure is not related to any disagreement with the Board or members of management concerning corporate strategy or financial or accounting matters.

16:13 EDT PetIQ expects to open 100 new wellness centers in 2021 - The company said, "The Company expects to open approximately 100 new wellness centers in 2021 compared to its previously stated plan to open 130 to 170. The Company plans to begin construction on new wellness centers once all required in-center labor is hired given the current labor market. While the Company's outlook remains suspended due to the uncertainty from potential COVID-19 and Delta-variant related impacts to its business, it continues to have record year-over-year net sales and adjusted EBITDA results. The Company is optimistic the Services segment will continue to generate significant improvements to its operations in the fourth quarter of 2021. As the impacts to the Company's Services segment lessen and become more predictable, it will then be in a better position to provide formal guidance. For the Products segment, the Company maintains its strong visibility to another year of solid sales growth and Adjusted EBITDA margin expansion. The Company continues to expect full year 2021 incremental EBITDA contribution from Capstar(R) of greater than $20 million. Long-term, the Company remains confident in achieving its strategic and financial objectives."

16:11 EDT Royal Gold increases stream segment, royalty stream sales volume guidance - Royal Gold increased its guidance for total stream segment and royalty sales volume to a range of between 180,000 and 190,000 GEOs for the 6-month transition period ending December 31, 2021. For the same period, depreciation, depletion and amortization expense is expected to range between $525 and $575 per GEO, and the effective tax rate is expected to range between 18% and 22%. Other than potential remaining conditional funding at Khoemacau of $26.5 million and potential exploration and resource payments under the NX Gold Stream of $10 million, Royal Gold has no other project capital commitments or financing obligations.

16:04 EDT Qualcomm exceeding 2019 Analyst Day targets, says CEO Amon - "As of fiscal 2021, we are exceeding our 2019 Analyst Day targets for revenue growth and diversification and operating margin expansion, while more than doubling our year-over-year Non-GAAP EPS," said Cristiano Amon, President and CEO of Qualcomm Incorporated. "We are well positioned to continue to lead in mobile and enable the digital transformation of industries with our broad portfolio of relevant technologies. Our results across RF front-end, Automotive and IoT attest to the success of our technology roadmap and revenue diversification strategy."

16:02 EDT Booking Holdings CEO 'pleased' by 'another quarter of sequential improvement' - "We are pleased to report another quarter of sequential improvement in room night trends, which was primarily driven by better results in Europe. Revenue in our seasonally strongest third quarter was $4.7 billion, which was more than double the amount of revenue we recognized in the second quarter of 2021. We are encouraged by the signs of recovery we saw in many parts of the world in the third quarter, and our teams are working hard to continue to strengthen our company's position and execute against our strategic priorities," said Glenn Fogel, CEO of Booking Holdings.

15:18 EDT Kennedy Wilson raises quarterly dividend 9% to 24c per share - The company will pay a quarterly dividend to common shareholders of record as of December 31, 2021 with a payment date of January 6, 2022.

14:51 EDT General Dynamics announces $190M cloud contract from USPTO - General Dynamics Information Technology, or GDIT, a business unit of General Dynamics, announced that it has been awarded a five-year, $190M contract from the United States Patent and Trademark Office, or USPTO, for enterprise cloud modernization. Under this contract, which was awarded in September, GDIT will deliver a scalable, hybrid multi-cloud platform to modernize USPTO's IT infrastructure, the company stated.

14:24 EDT Robinhood now supports DSPs through IPO Access - Robinhood said that it now supports Directed Share Programs, or DSPs, through IPO Access. A DSP gives an issuing company the chance to set aside a certain amount of shares, at the IPO price, for a specific group of people. Sometimes known as a "friends and family" offering, this group usually includes employees, valued customers, vendors, or others who have a relationship with the company. DSPs are designed to recognize "friends" of the company by giving them an opportunity to buy shares at the IPO price. They can facilitate meaningful community-driven interactions between companies going public and the individuals who have been a part of their journey leading up to the IPO. In a DSP, the company reserves a portion of IPO shares for a specific group of people and Robinhood helps distribute these shares to select individuals through the program. If those invited to participate in the DSP by the issuer are interested in investing in the company's IPO, they can use the Robinhood app or open an account if they're a new customer to request shares at the initial public offering price. Reference Link

14:07 EDT Cleveland-Cliffs partners with U.S. DOE for Better Climate Challenge initiative - Cleveland-Cliffs announced that it has entered into a partnership with the U.S. Department of Energy as part of the Better Climate Challenge initiative, a new government-sponsored effort challenging organizations to set ambitious, portfolio-wide GHG emission reduction goals. The initiative provides additional opportunities for peer exchange and technical assistance to meet the urgent call to mitigate the impacts of climate change. As part of the partnership, the DOE will provide technical assistance and opportunities to learn and share actionable best practices for carbon reduction. Through the Better Climate Challenge, Cleveland-Cliffs remains committed to reducing greenhouse gas emissions 25% by 2030 from 2017 levels. This goal represents combined Scope 1 and Scope 2 GHG emission reductions on a mass basis across all operations. The company is also a proud partner of the Better Plants program. Lourenco Goncalves, Chairman, President and CEO, said, "We are pleased to now be working hand-in-hand with the U.S government in our efforts to meet our 2030 emissions target, and also share what we believe are global best practices in minimizing greenhouse gas emissions. Our operations are among the most environmentally friendly of their kind in the world, but we still continue to make improvements to reduce carbon emissions. This includes the use of HBI in blast furnaces, the increased utilization of prime scrap in our BOFs, and with that, the corresponding reduction in coke rate. We appreciate the DOE's recognition of our accomplishments thus far and look forward to reporting on our continued emissions reduction progress."

13:49 EDT ConnectOne Bancorp CEO Sorrentino sells 30,000 common shares - In a regulatory filing, ConnectOne Bancorp chairman, president, and CEO Frank Sorrentino III disclosed the sale of 30,000 common shares of the company on November 2 at a price of $34.1222 per share.

13:35 EDT Hollysys down over 20% after disclosing change in auditor - In a regulatory filing last night, Hollysys Automation Technologies reported that on October 31, 2021, the company engaged Union Power HK CPA Limited as the company's independent registered public accounting firm. Union Power succeeds Ernst & Young Hua Ming, which previously was the independent registered public accounting firm providing audit services to the company. "The change of the company's independent registered public accounting firm was approved by the audit committee and the board of directors of the Company. EY's audit report on the company's consolidated financial statements as of and for the year ended June 30, 2020 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the audit for year ended June 30, 2020, there was no disagreements, as defined in Item 16F (a)(1)(iv) of Form 20-F and the related instructions, between the company and EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to the satisfaction of EY would have caused them to make reference thereto in their report on the consolidated financial statements for such year. As of the date of EY's resignation, EY had not issued their audit reports on the company's consolidated financial statements for the year ended June 30, 2021. As disclosed in the company's Form 12b-25 dated November 2, 2021, the company is late in filing its annual report on Form 20-F for the year ended June 30, 2021 with the Securities and Exchange Commission. The company is working closely with EY and Union Power to ensure a seamless transition," the filing stated. In Wednesday afternoon trading, Hollysys shares trading in New York are down $4.19, or about 22%, to $15.19.

13:19 EDT Square says Cash App now available to users aged 13 and up with approval - The twitter account of Square's Cash App tweeted: "Cash App is now available to everyone 13+, with parent or guardian approval. Send, save, and design your own debit card." Reference Link

12:58 EDT CMA extends inquiry period into Sony acquisition of Kobalt Music - The United Kingdom's Competition and Markets Authority extended the reference period for Sony Music Entertainment's acquisition of the AWAL business and the Kobalt Neighbouring Rights business from Kobalt Music Group "until Sony provides the documents and information to the satisfaction of the CMA, or the CMA publishes its decision to cancel the extension." Reference Link

12:42 EDT Change Healthcare no longer issuing guidance due to OptumInsight deal - The company said, "Due to the proposed transaction with OptumInsight, we will no longer be providing financial guidance." On January 5, 2021, OptumInsight and Change Healthcare (CHNG) agreed to combine. Under the terms of the merger agreement, UnitedHealth Group (UNH), through a wholly-owned subsidiary, will acquire all of the outstanding shares of Change Healthcare common stock for $25.75 per share in cash.

12:07 EDT Facebook to pay creators bonuses for new subscribers until end of 2021 - Facebook (FB), which is in the process of rebranding as Meta (MVRS), stated in a blog post: "In June 2020, we opened up fan subscriptions, now called Subscriptions, to more creators and today we're sharing a number of exciting updates that will help creators make more money, earn a sustainable living and have more control over the businesses they build on Facebook... To help creators grow their subscription businesses, Facebook will pay creators a bonus of $5 - $20 for every new subscriber they get from now until the end of 2021. This new bonus program is part of the company's commitment to invest over $1 billion in creators through 2022. Creators can earn a bonus of up to $10,000 over the course of the program. It's invite-only in all 27 markets where the Subscriptions feature is available to creators. We hope to expand this bonus program and others in the coming months to help more creators build sustainable subscription businesses on Facebook... Earlier this year, as part of our commitment to supporting creators, we shared that Facebook would not collect any fees from creators on Subscriptions purchases until 2023, at the earliest. Creators, however, must still forfeit 15-30% of their earnings to companies like Apple whenever people purchase Subscriptions within the Facebook app on mobile devices. For recurring payments like subscriptions, this adds up quickly since that fee is paid every single month. Starting today, we're offering creators the ability to direct people to a website to complete their Subscriptions purchase using Facebook Pay. When people purchase Subscriptions from this website on web or mobile, creators will be able to keep 100% of the money they earn, excluding taxes." Reference Link

12:05 EDT Waymo to bring autonomous cars to New York City - Alphabet's Waymo said that, starting tomorrow, it is bringing Waymo Driver to New York City for mapping and testing purposes. "New York City is the most densely populated city in the country, with bustling avenues, unusual road geometries, complex intersections, and constantly evolving layouts, and we've designed the Waymo Driver to handle these types of complex and dynamic activities that define city driving," Waymo said in a blog post. "Our vehicles will be manually operated by autonomous specialists at all times, to help us scale and advance our technology in support of our mission to make roads safer." "New Yorkers will begin to see Waymo vehicles driving in Manhattan this week, primarily south of Central Park," the Alphabet unit continued. "Our operations will extend down through the city to the Financial District and also out to a small section of New Jersey through the Lincoln Tunnel. We'll be manually driving with five hybrid Chrysler Pacificas on the street during daylight. Later, we'll manually drive several of our zero-emission Jaguar I-PACEs equipped with our latest technology on the same streets in Manhattan, as we continue learning from NYC's busy traffic and unique geometric features. The insights we'll gain will help the Waymo Driver improve its ability to perceive and predict the actions of other road users in dense urban areas." Reference Link

12:02 EDT Turquoise Hill falls -18.6% - Turquoise Hill is down -18.6%, or -$2.35 to $10.25.

12:02 EDT Unisys falls -19.3% - Unisys is down -19.3%, or -$5.09 to $21.36.

12:00 EDT Veritiv rises 23.9% - Veritiv is up 23.9%, or $26.68 to $138.45.

11:32 EDT Thomas Dohmke to become CEO of Microsoft's GitHub - Nat Friedman said earlier in a blog post: "This morning, I sent the following post to the GitHub team. TL;DR: I'm moving on to my next adventure, and Thomas Dohmke - currently Chief Product Officer - will be GitHub's next CEO. I will become Chairman Emeritus, which fulfills my lifelong ambition of having a title in Latin. My heartfelt thanks to every Hubber and every developer who makes GitHub what it is, every day... With all that we've accomplished in mind, and more than five great years at Microsoft under my belt, I've decided it's time for me to go back to my startup roots. What drives me is enabling builders to create the future. I've loved working with and learning from developers who are building new tools and new projects, solving thorny problems, and creating magic out of code. That's why I'm moving on to my next adventure: to support, advise, and invest in the founders and developers who are creating the future with technology and tackling some of the biggest opportunities of our day." The leadership changes are effective November 15, Friedman stated. Reference Link

11:10 EDT Marsh McLennan acquires Southwest Truck Insurance Agency, terms not disclosed - Marsh McLennan Agency announced the acquisition of Southwest Truck Insurance Agency, an independent agency in Irving, Texas. Terms of the acquisition were not disclosed. Founded in 1986, Southwest Truck Insurance specializes in business insurance solutions for the trucking industry, with expertise in domestic and cross-border trucking operations, serving clients in the US and Mexico. All of Southwest Truck Insurance's team, which is led by John Phillips, President, will join MMA.

11:02 EDT Morgan Stanley announces 2030 targets for net-zero financed emissions commitment - Morgan Stanley announced new steps towards its commitment to reach net-zero financed emissions by 2050. Building on its commitment to finance $1T towards the Sustainable Development Goals, including $750MM of financing to drive the climate transition, Morgan Stanley has set 2030 interim targets for three sectors: Auto Manufacturing, Energy and Power. In September 2020, Morgan Stanley became the first major U.S.-headquartered financial services firm to commit to net-zero financed emissions by 2050. The release of the Firm's first interim targets represents an important milestone in support of its 2050 commitment. For each sector, Morgan Stanley is taking an approach that examines its financed emissions relative to client financing commitments. This will help the Firm align the relative carbon emissions footprint of its lending portfolios with science-based sector pathways to reach net-zero by 2050. Each sector target covers Scope 1, Scope 2 and Scope 3 emissions and all greenhouse gases and is inclusive of the corporate lending portfolio. The targets are: Auto Manufacturing: -35%; Energy: -29%; Power: -58%.

10:08 EDT Sorrento Therapeutics receives ANVISA approval for COVISTIX in Brazil - Sorrento Therapeutics announced receipt of approval from the Brazilian regulatory agency for COVISTIX in Brazil. COVISTIX manufacturing approval from ANVISA was published in the Brazilian government official journal on October 18th under registration CNPJ 17700763/0001-48, resolution #3951. COVISTIX marketing authorization from ANVISA was published in the Brazilian government official journal on November 3rd under the same registration, with reference # 25351.041767/2021-72 / 80961800001. The registration will be held for Sorrento by FUTURA Ltd, a highly respected local partner for hospitals and direct point of care distribution of prescription drugs and health products, while SYNOVA Ltd will distribute the test among their client network of diagnostic laboratories. This approval is expected to allow immediate commercial deployment in Brazil and in multiple Latin American countries with close ties to the Brazilian market.

10:02 EDT CVS Health announces availability of Pfizer-BioNTech COVID-19 pediatric vaccine - CVS Health (CVS) announced that select CVS Pharmacy locations will be offering a two-dose primary series of the Pfizer (PFE) and BioNTech (BNTX) COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday, November 7, upon receipt and confirmation of vaccine supply. This follows authorization of the vaccine by the Centers for Disease Control and Prevention based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration Emergency Use Authorization.

10:00 EDT Tupperware Brands falls -14.0% - Tupperware Brands is down -14.0%, or -$3.28 to $20.18.

10:00 EDT BlueLinx rises 16.9% - BlueLinx is up 16.9%, or $7.91 to $54.67.

10:00 EDT R.R. Donnelley rises 36.5% - R.R. Donnelley is up 36.5%, or $2.41 to $9.01.

09:47 EDT Ternium falls -10.2% - Ternium is down -10.2%, or -$4.72 to $41.65.

09:47 EDT PROG Holdings rises 20.8% - PROG Holdings is up 20.8%, or $8.56 to $49.76.

09:47 EDT R.R. Donnelley rises 37.4% - R.R. Donnelley is up 37.4%, or $2.47 to $9.07.

09:43 EDT Humana sees FY22 earnings growth at lower end of LT 11%-15% range - Comments taken from Q3 earnings conference call.

09:33 EDT Rimini Street appoints Kevin Mease as CPO - Rimini Street announced the appointment of Kevin Mease as its first chief product officer and the appointment of Bill Carslay as the first group vice president and general manager of Global Professional Services. Additionally, the Company appointed Jennifer Perry as the first group vice president and general manager of SAP Services and Frank Reneke as the first group vice president and general manager of Oracle Services. These new roles were created to accelerate Rimini Street's multi-product strategy, deepening the focus on evolving and developing a best-in-class product portfolio that delivers better outcomes than competitive solutions and excellent client experiences, extend the Company's vision and leadership position in the industry and contribute to the Company's growth. All report directly to Rimini Street's chief operating officer, Gerard Brossard. Prior to joining Rimini Street, Mease served as vice president of product management for talent acquisition provider Jobvite where he led organizational growth and innovation

09:32 EDT Nutanix appoints Dominick Delfino as chief revenue officer - Nutanix (NTNX) announced the appointment of Dominick Delfino as chief revenue officer, effective December 6. Delfino will be responsible for leading the company's worldwide sales organization including sales engineering, sales operations, inside sales, OEM sales, and channel sales. Delfino brings more than 20 years of global sales experience, having led software sales and system engineering teams at multiple technology and software companies. Most recently, Delfino was chief revenue officer at Pure Storage (PSTG).

09:29 EDT Ford reports October U.S. vehicle sales 175,918, down 4% - Continuous improvement in inventories and new products made Ford the best-selling automaker in America for the second month in a row, which was last accomplished 23 years ago. Retail sales improved 16 percent, relative to September, with retail share up 1.6 percentage points. We also had our third consecutive month with over 30 percent of our retail sales coming from customer orders, while also adding 77,000 new orders in October. F-Series, strong SUV sales driven by Bronco, Bronco Sport, Mustang Mach-E and the first full month of Maverick sales really fueled our performance," said Andrew Frick, vice president, Ford Sales U.S. and Canada.

09:24 EDT Petros Pharmaceuticals reports 476% y-o-y growth of Stendra tablet sales - Petros Pharmaceuticals announced a 476% growth year-over-year of Stendra tablet sales as part of an exclusive digital health marketing agreement with Hims & Hers Health, a multi-specialty telehealth platform focused on providing personalized health and wellness experiences to consumers. Stendra is currently FDA-approved in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.

09:19 EDT Forward Air buys assets of BarOle Trucking, trucking assets of TKI Intermodal - "Forward Air is executing a growth strategy that involves organic infrastructure investments, such as its ongoing LTL network expansion, as well as inorganic investments, including acquisitions of complementary businesses. Our primary focus is to pursue accretive acquisitions that complement or expand the Expedited LTL division, while continuing to grow our intermodal segment with strategic acquisitions. As part of the inorganic growth strategy, Forward announced that it has entered into two separate agreements to acquire the assets of BarOle Trucking, . and the trucking-related assets of TKI Intermodal . These acquisitions are a part of the company's strategy focused on infrastructure investment to advance intermodal transportation capabilities and market leadership, while also gaining additional storage yards, chassis, and drivers. The acquisitions are expected to add $25M in revenue for the company and more than 82 new employees, including 95 drivers -- quadrupling Forward's total number of drivers in the Minneapolis Intermodal market. "The trucking and logistics industry is under unprecedented pressure, especially within the intermodal market, as we have seen higher demand than normal," says Tom Schmitt, Chairman and CEO of Forward Air. "The acquisitions are a continuation of our business strategy, empowering us with the additional resources necessary to meet growing customer demand while driving efficiency, market expansion, and industry-leading career opportunities." As with all of Forward's acquisitions in this space, the company was eager to seek BarOle, the largest intermodal carrier in the Twin Cities, and TKI, a Minneapolis-based freight shipping company that specializes in container drayage transportation and storage, due to their equal focus on quality service with cultures compatible with Forward Intermodal.

09:14 EDT Poet Technologies raises $14M for 2016 warrants - POET Technologies announced the Company raised approximately $14.1 million on the exercise of the C$0.52 warrants that were issued as part of its public offering in 2016. The warrants expired at the close of business yesterday, November 2, 2021. Since the original date of issuance on November 2, 2016, a combined 33,867,000 warrants were exercised of the total 34,800,000 warrants issued, generating gross proceeds of approximately $14.1 million. 13,115,750 of these warrants were exercised since June 30, 2021, netting the Company approximately $5.4 million in additional capital. The Company is also reporting that its unaudited cash balance subsequent to the expiration of warrants on November 2, 2021 was approximately $23.8 million.

09:11 EDT Berkshire Grey announces Robotic Shuttle Product Sortation solution - Berkshire Grey announced general availability of its Robotic Shuttle Product Sortation solution for order fulfillment. The system supports filling eCommerce orders through stores and in-person shopping by automating store replenishment, allocation order processing, split-case cross docking, sortation, and packing. RSPS increases processing capacity and throughput for existing operations without adding labor, helps right-size store inventories, and enables eCommerce fulfillment from stores to scale. Following a series of successful installations at major U.S. retailers, the solution is now generally available for global deployments.

09:08 EDT MaxCyte appoints Richard Douglas as chairman of the board - MaxCyte (MXCT) announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board. Richard Douglas has been a Board Member since February 2018. He succeeds J. Stark Thompson, PhD, who previously announced his decision not to seek re-election. Dr. Thompson will remain as a consultant to MaxCyte. Dr. Douglas is a veteran pharmaceutical executive who presently serves as an adviser at RedSky Partners, Chair of the Board of Aldeyra Therapeutics (ALDX), and Chair of the National Advisory Board of Innovation Partnerships at the University of Michigan.

09:06 EDT Velodyne Lidar founder issues statement regarding board changes - David Hall, the beneficial owner of approximately 42.9% of the outstanding common stock of Velodyne Lidar, issued the following statement in response to the company's November 1 announcement and Form 8-K filing regarding changes to its board: "While we welcome the news of Brad Culkin's retirement from the Board, it does not remedy the fact that we believe Chairman Michael Dee continues to lead Velodyne Lidar down the path of financial ruin. During Mr. Dee's tenure, Velodyne Lidar has fallen from its position as a global leader in lidar technology and innovation, and the Board has undertaken a series of anti-stockholder actions that has, in our view, resulted in insular corporate governance, troubling underperformance and strategic incompetency. In its latest affront to stockholders, the Company reported that Mr. Dee has been reclassified from a Class II director to a Class III director, in an apparent attempt to avoid having him stand for re-election at next year's Annual Meeting, which would have provided Velodyne Lidar's stockholders an opportunity to voice their opinions on his performance with their votes and could have resulted in him being voted off the Board. Stockholders may not have noticed this action, because although the Company issued a press release to announce Board matters, including Mr. Culkin's retirement, it did not mention this self-serving shift from Class II to Class III for Mr. Dee in the press release. Rather, the Company elected to tuck this disclosure into a regulatory filing in one sentence at the end of an unrelated paragraph. Investors not reading the fine print would have completely missed this shift - likely the result Mr. Dee and the Company intended. I believe this approach to disclosure is just another example of the culture of obfuscation that Mr. Dee has promulgated at the Company and the lack of transparency with stockholders that I can only assume he considers acceptable. I also find it ironic that the Board approved this shift in classes and reported it in this manner on the same day that it touted the appointment of a 'corporate governance expert' to the Board. I urge stockholders to consider the Board's actions carefully - if the Board was truly concerned with restoring a culture of integrity and good governance, as it would have its stockholders believe, why would it engage in such a brazen entrenchment maneuver? Unfortunately, this move appears to be the latest in a troubling pattern of stockholder disenfranchisement actions undertaken by the incumbent Board. Stockholders will surely remember how the Board manipulated the Company's corporate machinery in a similar fashion last February by transitioning director Christopher Thomas from a Class I director to a Class II director to seemingly avoid having him stand for re-election at this year's Annual Meeting. Will this Board ever give Velodyne Lidar's stockholders the opportunity to exercise their stockholder rights and vote on Messrs. Dee and Thomas' positions as directors or will this shell game continue, with Messrs. Dee and Thomas becoming Class III and Class I directors in the near future? Stockholders should rest assured that I will continue to fight on their behalf to help urge Velodyne Lidar to embrace good corporate governance, revitalize its integrity-rich culture and return to its position at the forefront of innovation and engineering excellence."

09:05 EDT My Size's measurement solution selected by UAE uniform provider Threads - MySize's AI-drive measurement solution has been selected by Threads of the UAE. Threads is one of the largest manufacturers and distributors of School & Corporate wear uniforms in the UAE. Established in 2010, Threads supplies 90 Schools, servicing more than 200,000 students and various corporate institutions, including security, transport, hotel, restaurants and others.

09:04 EDT Jack Henry CFO and CTO both retiring in June 2022 - Jack Henry CFO and Treasurer Kevin Williams and Chief Technology Officer Ted Bilke have both informed the company of their intention to retire in June 2022. Jack Henry will be working with an executive search firm to identify and evaluate potential successors to replace Williams from a pool of internal and external candidates. Ben Metz, Head of Digital at Jack Henry, has been named Bilke's successor and will assume the role of Chief Digital & Technology Officer in January when Bilke steps down as CTO. Bilke will remain with the company until his retirement to assist Metz with the transition.

09:03 EDT Pegasystems announces collaboration with Google Cloud - Pegasystems (PEGA) announced a collaboration with Google Cloud (GOOG, GOOGL) that will help improve experiences in healthcare with better data insights and personalization. This partnership between Pega and Google Cloud will bring together the capabilities of Google Cloud's Healthcare Data Engine and Pega's suite of intelligent healthcare solutions. Organizations will be better positioned to deliver optimal care and health outcomes to millions of people by combining Google Cloud's ecient, comprehensive data platform and Pega's personalized recommendations. This partnership with Google Cloud will allow Pega's clients to congure their applications so Google Cloud's Healthcare Data Engine -- which enables advanced analytics and AI in a secure, compliant, and scalable cloud environment -- seamlessly works with Pega's healthcare solutions. These solutions include Pega Care Management, Pega Customer Service for Healthcare, Pega Sales Automation for Healthcare, and Pega Customer Decision Hub. Google Cloud's Healthcare Data Engine harmonizes data from multiple sources, including medical records, claims, clinical trials, and research data, providing a foundation for Pega to facilitate and optimize millions of individualized, data-based conversations between consumers and health organizations, including service and claims interactions, and care navigation activities.

09:02 EDT BorgWarner awarded contract with global OEM for high voltage inverters - BorgWarner has secured a contract with a major OEM to supply high voltage inverters for battery electric vehicle platforms including a variety of passenger cars and trucks. The business award marks the company's largest major silicon carbide based inverter win and the first silicon carbide based inverter win in North America. The inverters leverage BorgWarner's Viper family of scalable power modules. The launch of the inverter is slated for 2024.

08:57 EDT Patterson-UTI reports October average 103 drilling rigs operating in U.S. - Patterson-UTI reported that for the month of October 2021, the company had an average of 103 drilling rigs operating in the United States. Average drilling rigs operating reported in the company's monthly announcements represent the average number of the Company's drilling rigs that were earning revenue under a drilling contract in the United States.

08:53 EDT Marriott 'could be in a position' to restart capital returns in 2H22

08:50 EDT Marriott 'not in a position' to give specific earnings, RevPAR guidance

08:48 EDT Big Lots will open Thanksgiving Day with 50% off all toys storewide - Big Lots will be open Thanksgiving Day from 7 a.m. to 9 p.m. at all locations nationwide with a 50% discount on all toys. In addition to extended hours on Thanksgiving Day, Big Lots will be open from 6 a.m. to 11 p.m. on Black Friday, Nov. 26, from 8 a.m. to 11 p.m. on Saturday, Nov. 27 and 9 a.m. to 10 p.m on Sunday Nov. 28.

08:47 EDT Conduent, MZ Technologie expand partnership for Holostop button - Conduent Transportation announced that the company has expanded its exclusive partnership with MZ Technologie to sell the Holostop, a contactless holographic stop button designed for use on public buses, to transport networks globally. This builds on the companies' original sales agreement for the French market.

08:41 EDT Futu Holdings announces $300M share repurchase program - Futu Holdings announced that its board of directors has approved a share repurchase program to repurchase up to $300 million worth of its own American depositary shares, representing its Class A ordinary shares, until December 31, 2022.

08:40 EDT Marriott sees recovery in business transient gradually continuing

08:38 EDT Sangoma Technologies announces share consolidation - Sangoma Technologies is pleased to announce that, as previously authorized by its shareholders, the Company is implementing a consolidation of its outstanding Common Shares on the basis of one new Common Share for every seven currently outstanding Common Shares. The Consolidation Ratio was determined by Sangoma's board of directors in accordance with the parameters authorized by the Company's shareholders at the special meeting of shareholders held on September 23, 2021. The consolidation took effect on November 2, 2021 and the Common Shares are expected to commence trading on the Toronto Stock Exchange on a post-consolidation basis beginning at the open of markets on November 8, 2021. Immediately prior to the consolidation there were 133,151,508 Common Shares issued and outstanding, and it is expected that there will be 19,021,614 Common Shares issued and outstanding following the consolidation, subject to rounding for any fractional shares. Assuming the issuance of the Common Shares comprising the Deferred Consideration and the Indemnification Holdback Amount in accordance with the Stock Purchase Agreement relating to the acquisition of StarBlue Inc., as amended by the Consolidation Ratio, it is expected that there will be 31,717,214 Common Shares issued and outstanding, subject to rounding for any fractional shares. No fractional shares will be issued as a result of the share consolidation and, in the case of a fractional interest, the number of post-consolidation shares to be received by a shareholder will be rounded down to the nearest whole number of shares that such holder would otherwise be entitled to receive upon the implementation of the share consolidation. By way of example, if a shareholder held 100 pre-consolidation Common Shares, the shareholder will hold 14 Common Shares on a post-consolidation basis.

08:37 EDT Entourage Health CSO, CLO Jason Alexander steps down - The company said, "Entourage extends its gratitude to Jason Alexander, former Chief Strategy Officer and Chief Legal Officer, who was integral to the Company's acquisition of both Starseed Holdings and CannTx, as well as Entourage's growth and success over the past year. Jason has elected to step down from the management team, however the Company is pleased to confirm he will continue as a board director and head of the Governance Committee."

08:36 EDT Marriott: Global demand softened 'a bit' in August amid Delta variant - Says demand stabilized in September, rose in October. Comments taken from Q3 earnings conference call.

08:36 EDT Entourage Health appoints Joseph Mele as CCO, Pat Scanlon as head of cultivation - Entourage Health announced it has strengthened its executive team with key strategic appointments in the areas of commercial sales, marketing, and business development as well as product development, cultivation and supply chain. Concurrent with the recent closing of the Company's acquisition of craft cultivator CannTx Life Sciences Inc, Entourage announces the following: Joseph Mele is appointed Chief Commercial Officer. Most recently the Senior Vice President of Commercial Sales and Marketing at Entourage, Joseph oversees all revenue-generating commercial roles and activities. Pat Scanlon, co-founder of CannTx is appointed Head of Cultivation across all Company sites. Pat has over 15 years of experience in floriculture, commercial greenhouse operations and specializes in craft-grade cultivation, production and phenotyping. As Entourage looks to expand its craft cannabis operations and product development, Pat will oversee the Company's genetics activities and introduce new cultivars and craft practices. James Afara is appointed Vice President of Strategic Sourcing and Purchasing. Former Chief Operating Officer of CannTx, James has extensive experience in supply chain, business analytics and operations management.

08:35 EDT Discovery says finished Q3 with 20M paying DTC subscribers - Says upside of Warner Media merger is global DTC opportunity. Says less than half of Discovery+ subscribers are HBO Max subscribers. Says finished Q3 with 20M paying DTC subscribers. Says sees momentum continuing into Q4 despite comps getting tougher year-over-year. Says expects foreign exchange to have negative $15M impact on revenue and $10M impact on AOIBDA in Q4. Says there are supply chain issues. Says here will be material growth in advertising. Says linear platform will be around for a long time. Comments taken from Q3 earnings conference call.

08:34 EDT Summit Therapeutics appoints Gayko to board of directors - Summit Therapeutics announced that Dr. Urte Gayko, PhD, has been appointed to the Board of Directors, effective immediately. Dr. Gayko is currently the Senior Vice President of Drug Development & Regulatory Affairs at Nektar Therapeutics. Dr. Gayko previously served as the Global Head of Regulatory Affairs and Pharmacovigilance at Pharmacyclics.

08:33 EDT CGI Inc. selected by City of San Diego for IT support - CGI has been selected by the City of San Diego for a $84M, 4-year contract, with additional option years for a potential 10-year contract term, under which it will provide long-term IT support to meet the evolving requirements of key business applications operated by the City, including a growing portfolio of digitized services. CGI's support will ensure the City's 11,000 employees have the tools they need to provide the highest-value services to the residents of San Diego. CGI currently provides maintenance and system enhancements in support of nearly 300 citywide applications, and deploys local technical staffing for operational support and development. Moving forward, CGI will support new digital services including San Diego's online permitting system and a paperless real-time vaccine management solution used at City-run vaccination sites.

08:32 EDT Bloomin' Brands appoints Astrid Isaacs to Chief Technology Officer - Bloomin' Brands announced the appointment of Astrid Isaacs to Chief Technology Officer for Bloomin' Brands. She will lead the company's technology strategy and platforms, while overseeing the IT, Digital and Loyalty teams. Isaacs will also join the Executive Leadership Team. "Astrid's proven ability to develop and implement technology to enable growth and enhance customer service, while improving productivity, will create a great deal of value for our customers and our company," said David Deno, Chief Executive Officer of Bloomin' Brands. "Digital connections, whether with our customers, our operators or our restaurant systems, have become a lifeline in our brands and many others. Astrid's experience with well-known restaurant companies, including our operating environment, brings a familiar yet fresh approach to our team as we continue to meet the needs of our customers wherever and however they wish, in their homes, offices, or in our dining rooms."

08:27 EDT Timber Pharmaceuticals announces pricing of $15M public offering - Timber Pharmaceuticals announced the pricing of its previously announced underwritten public offering of 23,437,500 shares of its common stock and accompanying warrants to purchase up to an aggregate of 23,437,500 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $0.64 per share of common stock and accompanying common warrant, less underwriting discounts and commissions. The warrants have an exercise price of $0.70 per share, are exercisable immediately, and will expire five years following the date of issuance. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. In addition, Timber has granted the underwriter a 30-day option to purchase up to an additional 3,515,625 shares of its common stock and/or warrants to purchase up to an additional 3,515,625 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Timber, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received upon exercise of the warrants to purchase common stock and the underwriter's option to purchase additional shares of common stock and/or warrants, are expected to be $15 million. This offering is expected to close on or about November 5, 2021, subject to customary closing conditions. Timber intends to use the net proceeds from the offering for general corporate purposes, including, but not limited to, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the Company's technologies, and licensing activities related to the Company's current and future product candidates and working capital

08:25 EDT Cognition Therapeutics adds Ellen Richstone to board of directors - Cognition Therapeutics announced the addition of Ellen Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Richstone currently serves on the boards of three publicly traded companies.

08:23 EDT ShockWave Medical increase some hospital outpatient payments - Shockwave Medical announced that as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System, OPPS, final rule, the Centers for Medicare & Medicaid Services, CMS, has reassigned the payment for peripheral IVL procedures performed on above the knee arteries in the hospital outpatient setting. The resulting payment increases will become effective January 1, 2022. As part of the 2022 OPPS final rule, CMS has announced new Ambulatory Payment Classification assignments for three Healthcare Common Procedure Coding System codes that describe peripheral IVL procedures performed in lower extremity arteries in the outpatient hospital setting. The three HCPCS codes affected describe procedures in iliac, femoral and popliteal arteries when IVL is performed by itself or adjunctively with drug coated balloons, stents or atherectomy. The new APC assignments will increase the payments hospitals receive for these procedures. "We appreciate CMS's collaborative relationship and their swift action in reassigning payment levels for IVL performed above the knee, as the data acknowledge the resources associated with performing IVL in these patients. Importantly, we believe the APC reassignment of these HCPCS codes and subsequent increased payment for IVL procedures performed ATK will further facilitate access to IVL technology for Medicare patients," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "We would like to acknowledge CMS for making an exception to this year's standard ratesetting process by considering calendar year 2020 data when determining appropriate payment levels for the new peripheral IVL code set. We are also grateful for the support that came from CMS' Hospital Outpatient Physician Advisory panel and medical societies during the public comment period."

08:22 EDT Inspired Entertainment signs online Virtual Sports contract with Mozzart - Inspired Entertainment has signed a contract to launch its best-in-class interactive Virtual Sports content with Mozzart, an iGaming operator in Eastern Europe. Inspired has agreed to supply Mozzart with the Virtual Plug & Play solution, which will allow Mozzart's players to access multiple Virtual Sports online. Mozzart has agreed to deploy Inspired as its primary Virtual Sports channel across all brands and territories.

08:21 EDT Inovio's Phase 3 COVID-19 vaccine candidate trial approved in India - Inovio has received authorization from India's Central Drugs Standard Control Organization's Drug Controller General of India to proceed with the Phase 3 segment of its global Phase 2/3 trial, INNOVATE , in India for INO-4800, its DNA vaccine candidate for COVID-19. Inovio is partnering with Advaccine Biopharmaceuticals to conduct the INNOVATE Phase 3 segment in multiple countries in Latin America, Asia, and Africa. Regulatory authorization in India follows authorizations from health authorities in Brazil, Philippines, Mexico and Colombia. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19. INNOVATE's Phase 3 segment builds upon the Phase 2 segment, which was conducted in the U.S. Interim Phase 2 data showed INO-4800 to be well-tolerated and immunogenic in adults 18 and older. INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and T cell responses, against variants of concern.

08:20 EDT Unity Biotechnology reports granting of employment inducement awards - UNITY Biotechnology announced that from October 19, 2021, through November 2, 2021, the Compensation Committee of the Board of Directors granted two new employees stock-based awards covering an aggregate of 190,000 shares of UNITY common stock, including options to purchase an aggregate of 160,000 shares of UNITY common stock and one grant consisting of 30,000 restricted stock units which will vest on the one-year anniversary of the vesting commencement date. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

08:19 EDT Advaxis announces ISS recommends stockholders vote 'FOR' merger - Advaxis announced that leading proxy advisory firm Institutional Shareholder Services, ISS, issued a report on November 1, 2021, recommending that Advaxis stockholders vote "FOR" the merger of the Company with Biosight and recommends voting "FOR" all proposals, at the Company's Special Meeting scheduled for November 16, 2021. The ISS recommendation stated, "The board ran what appears to have been a thorough strategic review process, corresponding with over 200 potential counterparties on a broad variety of transaction types, and no competing offers have been publicly disclosed since announcement. The strategic rationale also appears logical, as it will diversify the pipeline of product candidates, and is expected to result in a combined company with a more stable financial position. In light of these factors, support for the proposal is warranted." In addition, in recommending stockholders vote "FOR" the reverse stock split proposal, ISS highlighted "the reverse split may enable the company to maintain listing of its common stock on the Nasdaq Capital Market."

08:17 EDT Mammoth Energy issues Notice of Proposed Settlement of Derivative Action - Mammoth Energy issued the Notice of Proposed Settlement of Derivative Action to its stockholders relating to the pending derivative action disclosed by Mammoth in its reports filed with the SEC, which Notice was given in accordance with the Court order Preliminarily Approving Derivative Settlement and Providing for Notice dated October 28. In September 2019, four derivative lawsuits were filed, on behalf of Mammoth against its officers and directors, one of which was subsequently dismissed. The other three were consolidated by the Court. The terms of the Stipulation require that, in exchange for the full release, discharge and dismissal with prejudice of the claims asserted against the defendants in the derivative action, the individual defendants will cause the insurers under Mammoth's Directors' and Officers' insurance policy to pay $1.5M to Mammoth, which Mammoth will use for general corporate purposes; and Mammoth will adopt certain corporate governance reforms to enhance its governance policies. Additionally, the Stipulation provides that the individual defendants will cause the D&O insurers to pay, subject to Court approval, a separate payment of $0.5M to plaintiffs' counsel for their attorneys' fees and expenses. The Court has set a hearing date for January 7, 2022 to consider the final approval of the settlement.

08:17 EDT CVS Health says 'exceeded expectations' in Q3 - Says strong revenue growth in all three businesses in Q3. Says continues to make "measurable progress" with overall strategy. Says "guiding towards a strong year end." Comments taken from Q3 earnings conference call.

08:15 EDT Cytek Biosciences acquires Tonbo Biosciences cell analysis business - Cytek Biosciences announced that it has acquired the cell analysis business of Tonbo Biosciences, which includes a portfolio of life science research reagents related to cell preparation, flow cytometry, molecular immunology/PCR and cell culture covering application areas across immunology, apoptosis, and immunoprofiling. The addition of the Tonbo Biosciences portfolio of reagents will enable Cytek to offer extended flow cytometry capabilities. "Tonbo's reagents meet the highest standards of quality and performance, making them a natural fit with our comprehensive suite of solutions for the cell analysis market," said Dr. Wenbin Jiang, president and CEO of Cytek. "Adding Tonbo's reagent offerings to our existing Full Spectrum Profilin platform is yet another example of our commitment to redefining what is possible in flow cytometry and offering a total solution to our users."

08:14 EDT Allena Pharmaceuticals receives Fast Track designation for ALLN-346 - Allena Pharmaceuticals announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration. ALLN-346 is in Phase 2 development for the treatment of hyperuricemia in gout patients with advanced chronic kidney disease.

08:13 EDT Bionano Genomics announces release of Bionano Solve, Access versions - Bionano Genomics announced the release of Bionano Solve version 3.7 and Bionano Access version 1.7 as available data solution upgrades for Saphyr systems installed in laboratories worldwide. Included in these updates are improvements in variant detection, as well as workflow simplifications and other benefits designed to support clinical research in inherited genetic diseases and cancer. All new Saphyr system installations will include these versions. New OGM capabilities include the means to detect more clinically-relevant variants such as absence of heterozygosity, AOH, and allelic imbalance, the first two classes of variations that are typically considered as sequence rather than structural variants. The updates will also enable users to visualize chromosomal AOH across the genome similarly to single nucleotide polymorphism microarrays. The new workflow enables all SVs detected by Solve and analyzed with Access to be named and classified using standard terminology according to the 2020 International System for Human Cytogenomic Nomenclature. "These ongoing improvements in the performance of our software for detecting SVs, as well as the tools for interpreting and reporting calls, continue to impress me," said Erik Holmlin, PhD, CEO of Bionano Genomics. "We believe this update is significant because of the AOH and allelic imbalance functionality we are introducing. With our acquisition of BioDiscovery now complete, we can begin work to integrate our variant detection technology with NxClinical's visualization, interpretation and reporting capabilities to offer a potentially outstanding window through which researchers can obtain the data to drive their science."

08:13 EDT 89bio appoints Kathy LaPorte to board of directors - 89bio announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte previously served as Chief Executive Officer and Board Member of Nodality Inc.

08:11 EDT Cara Therapeutics announces CEO transition - Cara Therapeutics announced that Christopher Posner, a current member of the company's Board of Directors, has been appointed President and Chief Executive Officer, effective November 9, 2021. Posner succeeds Dr. Derek Chalmers, who will transition to a Senior Advisor role. Posner joins the Company from LEO Pharma, the US affiliate of LEO Pharma A/S, where he was President and CEO. While at LEO, Posner was responsible for a portfolio of innovative medical dermatology products in atopic dermatitis, psoriasis, and rosacea. Posner has more than 23 years of global pharmaceutical management, sales and product launch experience.

08:10 EDT Integral Molecular enters antibody license agreement with AstraZeneca - Integral Molecular announced that it entered into an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers. Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.

08:07 EDT Anthem and kidney care company Somatus announce multi-year partnership - Somatus announced a long-term, multi-year partnership with Anthem. Together, Anthem and Somatus will change how kidney care is experienced and delivered for members of Anthem's affiliated Medicare Advantage plans, specifically individuals with chronic kidney disease, CKD, Stage 3, 4, and 5 and end-stage kidney disease, ESKD. Somatus' services are available to eligible CKD and ESKD members enrolled in Anthem-affiliated Medicare Advantage plans starting on November 1, 2021, and ESKD Chronic Special Needs Plans starting on January 1, 2022. In addition to this partnership, Anthem made a strategic investment in Somatus. Somatus' partnership with Anthem expands the Company's geographic footprint to 34 states and increases its kidney care lives under management to more than 150,000. The Company is currently partnered with 10 national and regional health plans, several dozen hospitals and health systems, and more than 19,000 primary care providers, nephrologists, and other specialists. The Company's impressive growth across all kidney care stakeholders reflects its demonstrated ability to improve quality of care and lower costs for patients with kidney disease. "Anthem is committed to providing access to innovative programs that meet each health plan member's unique healthcare needs," said Elena McFann, President of Anthem's Medicare business. "Investing in and partnering with Somatus ensures consumers with kidney disease enrolled in our affiliated health plans will receive industry-leading personalized, in-home care and resources they need to improve their health and wellbeing." As part of this collaboration, Anthem will enable bi-directional data exchange with Somatus via Anthem's Health OS, which is a comprehensive, cloud native, payor and provider agnostic platform for health that connects siloed health data and disparate technologies to drive deeper insights as well as reduce costs and complexity. The secure, bi-directional data exchange will transmit timely alerts on member admission and discharge to optimize care, simplify coordination with Anthem care management personnel, and enhance the consumer and provider experience.

08:05 EDT Biomea Fusion expects cash to sustain operations well into 2024 - As of September 30, 2021, the Company had cash, cash equivalents, restricted cash, and investments of $191.9 million.

08:01 EDT Revive, PharmaTher enter research collaboration agreement - PharmaTher Holdings (PHRRF) is pleased to announce it has entered into a research collaboration agreement with Revive Therapeutics Ltd. (RVVTF) to evaluate the delivery of psilocybin with PharmaTher's proprietary microneedle patch technology for neuropsychiatric disorders. PharmaTher is currently conducting IND-enabling research studies with MicoDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022. Research results with MicroDose-MN for psilocybin will be made available in November 2021. The Company is also conducting research studies with its MicoDose-MN and MacroDose-MN patch as a next generation delivery system for psychedelics with ketamine, 3,4-methylenedioxy-methamphetamine, lysergic acid diethylamide, and N, N-dimethyltryptamine. Also, the Company has decided to expand research to include ibogaine and mescaline. Partnership opportunities currently exist with MDMA, LSD, DMT, ibogaine and mescaline for specialty pharmaceutical companies seeking a differentiated and validated delivery system for psychedelics, desired pharmacokinetic profiles, intellectual property protection, cGMP microneedle patches for IND-enabling and clinical studies, and a clear clinical pathway towards FDA Phase 1 and 2 clinical studies in 2022. The Company's MicroDose-MN and MacroDose-MN patches have the potential to efficiently penetrate the stratum corneum layer, enable flexible drug load capacity and combinations, and control-release delivery, which may overcome the potential drawbacks of oral administration, subcutaneous injections, topical and nasal delivery systems. In addition to the potential of maintaining constant plasma levels for more than 24 hours, the MN patches aim to empower patients to dose their medication remotely, safely and conveniently rather than under supervision by a healthcare provider at a certified medical office. To achieve this, the Company will incorporate anti-tampering and anti-abuse features that would parallel the approach used for the tamper-resistant transdermal fentanyl patch.

07:57 EDT Revival Gold releases infill drill results at Haidee - Revival Gold is pleased to announce results from the first eight infill drill holes completed in the Haidee target area in connection with the Company's 2021 exploration program at the Beartrack-Arnett Gold Project located in Idaho, USA. Each of the eight holes reported below encountered above cut-off grade, near-surface oxidized gold mineralization. Highlights include: 1.15 g/t gold over 13.7 meters in AC21-078D; 0.42 g/t gold over 29.9 meters in AC21-074D; 0.77 g/t gold over 13.0 meters in AC21-073D; 0.43 g/t gold over 23.2 meters in AC21-072D; 0.47 g/t gold over 18.9 meters in AC21-071D.The 2021 drilling program at Haidee was designed to upgrade and expand the deposit's current Inferred heap leachable mineral resources. In addition, the program included drill holes to obtain engineering data for the planned late-2022 Pre-Feasibility Study. A total of 15 holes were completed with four holes drilled for geotechnical and hydrological purposes. Assay results for the remaining seven drill holes are expected by year end.

07:56 EDT Biogen announces data presentations at the 2021 CTAD Meeting - Biogen announced the company will present a variety of new data from its Alzheimer's disease product portfolio and clinical development pipeline at the upcoming annual Clinical Trials on Alzheimer's Disease conference, held November 9-12 virtually and in Boston, Massachusetts. Biogen's contributions to the conference are driven in part by analyses from the largest clinical trial dataset in early Alzheimer's disease research. This includes over 3,000 patients in Phase 3 trials and approximately 1,700 patients in the ADUHELM redosing trial, EMBARK. A late breaking presentation will highlight important new data from over 7,000 plasma samples from the ADUHELM Phase 3 trials that, for the first time, examines the effect of ADUHELM on plasma phosphorylated tau181 and its correlation to amyloid beta plaques and disease progression, as measured by clinical decline endpoints, in patients with early Alzheimer's disease. The accumulation of amyloid beta plaques and tangles of tau proteins in brain cells are the two defining pathologies of Alzheimer's disease. The data will be discussed at the virtual oral presentation and roundtable: "Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials," on Thursday, November 11, at 5:10 p.m. EST. Biogen will also present data from over 1,800 patients that were screened for the EMBARK re-dosing trial with ADUHELM, to shed light on the impact of stopping treatment in clinical trials. Patients who were enrolled in the ADUHELM trials when they were discontinued in 2019 later re-enrolled in the EMBARK trial, after a lengthy off-treatment period of an average of 1.7 years. Some of these patients had been on treatment for more than 4 years in the PRIME Phase 1b long-term extension, as well as for up to 18 months in the Phase 3 trials, EMERGE and ENGAGE. Disease progression and amyloid beta plaque levels during this extended discontinuation of Alzheimer's disease treatment will be examined in the Virtual Oral Presentation, "Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study," on Tuesday, November 9, at 8:00 a.m. EST. In addition, a poster titled, "Urgency to treat before it's too late: Daily transitions to moderate AD dementia in the US and Europe," will examine how many people are estimated to progress daily from mild cognitive impairment due to Alzheimer's disease to mild Alzheimer's disease, and from mild Alzheimer's disease to moderate

07:53 EDT CloudMD partner with Apotex Latinoamerica to drive expansion of health education - CloudMD Software & Services announces an expanded partnership with Apotex, a Canadian-based global pharmaceutical company, to provide Apotex Latinoamerica with its IMD Health digital education resource platform to support doctors, patients and individuals in Latin America and provide access to its database of health educational resources. The IMD platform will be available in Mexico, Costa Rica, Panama and Nicaragua. CloudMD and Apotex Latinoamerica have partnered to provide better access to healthcare resources for doctors and patients in Latin America. The partnership focuses on two core platforms: an integration into a Apotex-operated physician web portal and, integration into a public facing web portal. CloudMD's educational platform will provide access to peer-reviewed healthcare resources that will assist and support doctors and patients throughout their care journey. The platform has developed Spanish as a core language option on the offering which provides further opportunities for global expansion. Dr. Essam Hamza, CEO of CloudMD commented, "We are excited to announce an expansion of our partnership with Apotex into Latin America. Our IMD Health education platform has a robust database, and we feel very fortunate to be able to provide credible, trusted healthcare resources to practitioners and patients to support their health needs."

07:52 EDT CVS Health raises FY21 Health Care benefits revenue view to $80.7B-$81.9B - Prior view was $79.9B-$81.2B. Raises FY21 Pharmacy Services revenue view to $151B-$153.2B from $148.4B- $150.9B. Raises FY21 Retail/LTC revenue view to $97.8B-$99.1B from $94.3B-$95.6B. Expects vaccinations to continue into Q4 at a lower rate than Q3, and expects testing to modestly decline in comparison to Q3 levels.

07:52 EDT Lexaria Bioscience announces new study on DehydraTECH-CBD for hypertension - Lexaria Bioscience announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. "HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies," said Chris Bunka, CEO of Lexaria Bioscience Corp. "Outcomes from this study could support Lexaria's goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure." HYPER-H21-4 is expected to consist of 60 volunteers between the ages of 45-70 using three 150 mg doses of DehydraTECH-CBD, every day for the 6-week duration of the study. The study will use a double blinded, randomized cross-over design, and utilize a placebo control. Some volunteers will already be using leading standard of care hypertension drugs such as ACE inhibitors with or without diuretics to help evaluate the efficacy of DehydraTECH CBD with and without other hypertension treatments. The extended duration of the study will allow Lexaria to gather critical data monitoring extended use of DehydraTECH-CBD and will evaluate the potential for longer term health benefits. Study protocols are being readied for submission to the Independent Review Board and approval is anticipated by January, 2022. HYPER-H21-4 is more comprehensive than any work previously undertaken by Lexaria and many types of analysis will be performed including 24-hour ambulatory blood pressure arterial stiffness and autonomic balance; brain structure and function through brain magnetic resonance imaging blood biomarkers ; renal, hepatic, sleep quality / daytime sleepiness / sleep disorders; actigraphy, geriatric depression scale, perceived stress, and Beck anxiety inventory. The wide range of data collection could provide additional insights into the benefits of DehydraTECH-CBD that might otherwise remain hidden from view. HYPER-H21-4 is expected to produce an enormous amount of data that, if positive, should be supportive of Lexaria's plans to enter regulatory pathways anticipated to result in eventual regulatory approval to use DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. This study is entirely funded through the Company's existing cash resources and is not subject to any financing requirement.

07:50 EDT Aehr Test Systems receives $7.6M order for WaferPak Full Wafer Contactors - Aehr Test Systems announced it has received a $7.6M order from its lead silicon carbide test and burn-in customer for WaferPak full wafer Contactors to meet their increased production capacity needs. These WaferPaks are scheduled to be delivered over the next five months to accompany the FOX-XP systems previously ordered by this customer announced in September. Like the FOX-XP systems order, this order also includes down payments. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "These WaferPak Contactors accompany the previous $19 million order for FOX-XP production test systems from this customer to meet their capacity needs for testing silicon carbide devices used for power conversion in on-board and off-board electric vehicle chargers, as well as the traction inverters used in electric vehicle motor controllers. This customer, who is a leading Fortune 500 supplier of semiconductor devices with a significant customer base in the automotive semiconductor market, also expects demand for silicon carbide in other major markets, including home electric storage and solar power conversion. This order is for about two thirds of the WaferPaks needed to match the capacity of the FOX-XP systems this customer previously ordered, and we expect them to order additional WaferPaks to accompany the systems that are scheduled to be shipped over the next seven months. In addition to their forecast for additional WaferPaks this fiscal year, this customer forecasts significant additional system and WaferPak purchases, reflecting the growing demand for silicon carbide devices for electric vehicle and other applications that multiple industry forecasters and analysts expect to grow at a compound annual growth rate of more than 30% over the next decade."

07:48 EDT Verano Holdings appoints Destiny Thompson as Chief People Officer - Verano announced the appointment of Destiny Thompson as Chief People Officer, CPO. Thompson will lead all aspects of Human Resources including the further integration of a people first culture at Verano. Thompson was previously Chief Human Resources Officer at Stout, a private investment bank and advisory firm.

07:46 EDT Else Nutrition provides update on sales growth drivers for 2022 - LSE NUTRITION HOLDINGS is pleased to report on its planned key sales drivers for 2022: In September 2020 Else launched a single SKU on amazon.com, with Kids Shakes launch in July 2021. Monthly sales are growing at a rate of 10% AVG MoM with 60% repeat purchases with 650+ subscribers and are expected to accelerate as the product range grows substantially in 2022. In the first quarter of 2021 Else launched the Toddler product on Thrive Market and iHerb with solid MoM growth on these important platforms. In the fourth quarter of 2021 Else will start selling on Walmart's and Kroger's online platforms expanding its product range to include Kids Shakes on all 4 platforms. Else expects sales from these and from additional online platforms to be a key sales driver in 2022. In the first quarter of 2021 Else launched its Toddler product in Sprouts Farmers Markets and saw sales velocity grow steadily to over 1.1 UPWPS. In the third quarter of 2021 Else was listed with more than a dozen retailers and over 100 independents and co-ops representing 1,200+ doors combined, with majority of these coming online in late summer to early fall. Else continues to add additional products such as Kids Shakes to the currently listed stores and is in discussions for listing with dozens of natural food and grocery retailers representing more than 5,000 additional doors, and with key pharmacy retailers that represent more than 20,000 doors. In 2022 else plans to expand sales to more than 4,000 doors and continue to add to its product range. In 2021 Else started with the launch of a single powder product - Complete Plant Based Nutrition for Toddlers. By mid-year Else added Kids Shakes to its online range which grew rapidly to reach 30% of all e-store sales. Kids Shakes in Banana and Mango flavors will be added to retail store SKU's in fourth quarter of 2021, and in 2022 Else will add several new exciting product lines - Super Cereal in flavors for 6+ month babies will launch in first quarter of 2022, in 7 oz package. A non-organic Toddler product with a more affordable price point that will allow more babies to enjoy Else is planned to be launched in the first quarter of 2022. Ready to Drink, 8 fl. oz bottles, for Kids in multiple flavors will launch soon after. During 2022 the product range will grow to 10+ products and 20+ SKUs in the US and a product range is planned for Canada, Europe and the Far East. Based on current interest for Else from Canada in our e-store we know that demand in Canada for Else is very high. Canada regulations required the development of slightly different range of products, starting in the first quarter of 2022 Else plans to launch three products in Canada - Toddler Drink, non-organic; Kids Drinks, non-organic, in flavors; Super Cereal, organic, in flavors. Launch is planned to include all channels during 2022 - Else e-store, Amazon.ca, grocery and pharmacy retail chains, natural food retailers and independents, which over time is anticipated to grow to 12-15% of sales volume for North America.

07:44 EDT Revive Therapeutics, PharmaTher collaborate for development of psilocybin MN - Revive Therapeutics (RVVTF) announces it has entered into a research collaboration agreement with PharmaTher (PHRRF), a clinical-stage psychedelics biotech company, to evaluate the delivery of psilocybin with PharmaTher's proprietary microneedle, MN, patch technology for neuropsychiatric disorders. PharmaTher is currently conducting IND-enabling research studies with MicroDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinicals studies in 2022. Research results with MicroDose-MN for psilocybin will be made available in November 2021 by PharmaTher. Revive is building a specialty psilocybin-based product pipeline with the aim to treat mental illness, substance abuse and neurological disorders. Michael Frank, CEO of the Company commented, "We are maintaining our focus in building a unique psilocybin-based product portfolio through research collaborations, licensing and commercialization agreements with academic research institutions and specialty pharmaceutical companies. The collaboration with PharmaTher complements our psilocybin product offerings as potential treatments for mental illness, substance abuse and neurological disorders. We believe there is no one fits all product profile solution with psilocybin and that for psilocybin to be a next generation therapeutic, it will require different use and delivery forms to achieve the intended target indications. As such, we aim to become a leader in psilocybin-based solutions for unmet medical needs by collaborating with companies that have intellectual property and experience in their delivery technologies."

07:42 EDT Clean Harbors sees FY21 ees FY adjusted Ebitda $655M-$675M

07:41 EDT Joint Corp. names Jason Greenwood as Chief Marketing Officer - The Joint promoted Jason Greenwood to Chief Marketing Officer. Greenwood will continue to report to President and Chief Executive Officer Peter Holt.

07:38 EDT Plus Therapeutics to host KOL roundtable on ReSPECT GBM trial - Plus Therapeutics announced that it will host a key opinion leader roundtable discussion on the ReSPECT-GBM trial on Thursday, November 18, 2021, 4:00 to 5:00 p.m. ET. The webinar will feature a comprehensive discussion about the ongoing ReSPECT-GBM trial including key safety, tolerability, dosing, feasibility and efficacy data. Speakers will include: Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio and principal investigator of the ReSPECT-GBM trial, will provide an update on the trial and provide insight on the trial data. Toral Patel, M.D., Associate Professor, Department of Neurosurgery, UT Southwestern Medical Center, will provide her prospective on the use of convection enhanced delivery in neurosurgery. Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will discuss the technology behind 186RNL as well as an overview of the opportunities for radiotherapeutic development. The webinar is intended to provide a comprehensive discussion of the trial data and an opportunity for questions from analysts, physicians and advocacy groups. The ReSPECT-GBM Phase 1 clinical trial is evaluating the Company's lead investigational asset, Rhenium-186 NanoLiposome, in patients with recurrent glioblastoma. Dr. Brenner will also present ReSPECT-GBM data during a poster session on November 19, 2021, 7:30 - 9:30 p.m. ET, at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.

07:34 EDT BridgeBio doses first patient in Phase 1/2 clinical trial of BBP-812 - BridgeBio Pharma announced that the first patient has been dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational adeno-associated virus 9 gene therapy for the treatment of Canavan disease. Canavan disease is an ultra-rare and fatal disease that affects approximately 1,000 children in the United States and European Union. There are currently no approved therapies for the condition.

07:30 EDT Agios Pharmaceuticals announces key upcoming milestones - Host investor day on Nov. 17 to share updates on the company's research and development pipeline, as well as provide additional insights into the commercial launch strategy and expectations for mitapivat in PK deficiency. Initiate Phase 2/3 RISE UP study of mitapivat in sickle cell disease by year-end.

07:26 EDT Charles River sees LT adjusted EPS growth at faster rate vs. revenue - 2024 financial targets include: Low-double-digit organic revenue growth; Operating margin of ~22.5% in 2024; Non-GAAP EPS growth at a faster rate than revenue.

07:23 EDT Karyopharm sees cash, cash equivalents and revenues sufficient into mid-2023

07:22 EDT Main Street exits debt and equity investments in J&J Services - Main Street Capital is pleased to announce that it recently fully exited its debt and equity investments in J&J Services upon the sale of the company to a strategic acquiror. Founded in 2000 and headquartered in Nashville, Tennessee, J&J is a second-generation family owned and operated business providing roll-off dumpster and portable toilet rental services to an expansive base of residential, commercial and demolition customers. Main Street realized a gain of $11M on the exit of its equity investment in J&J, with this realized value representing an increase of $5M above Main Street's fair market value for this investment as of June 30th, 2021.

07:22 EDT Autolus Therapeutics expects cash to provide runway into 1H23 - Cash at September 30, 2021, totaled $173.1 million, as compared to $216.4 million at June 30, 202

07:19 EDT Scotts Miracle-Gro plans to repurchase up to $300M in shares in FY22 - The Company also said it plans to repurchase up to another $300 million in shares during fiscal 2022.

07:15 EDT Centene to sell majority stake In U.S. Medical Management - Centene announced that it has signed a definitive agreement to sell a majority stake in U.S. Medical Management, to Rubicon Founders; Valtruis, a WCAS company; Oak HC/FT; and HLM Venture Partners. Centene will retain a minority stake in USMM. The transaction is subject to clearance under the Hart-Scott Rodino Act and satisfaction of other customary closing conditions.

07:13 EDT Praxis Precision Medicines expects cash to fund operations into 2Q23 - As of September 30, 2021, Praxis had $314.4 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020. This increase of $17.8 million primarily reflects $98.4 million in net proceeds from the follow-on public offering of shares of our common stock in May 2021, partially offset by cash used in operations of $79.7 million during the nine months ended September 30, 2021. The company's cash, cash equivalents and marketable securities as of September 30, 2021 are expected to fund operations into the second quarter of 2023.

07:08 EDT Dick's Sporting, Nike create connected partnership - DICK'S Sporting Goods (DKS) and NIKE (NKE) have forged a transformative, connected partnership designed to enhance the shopping experience for DICK'S and NIKE customers. This first-of-its-kind collaboration will allow DICK'S and NIKE to each reach more customers and provide them with access to exclusive products, experiences and offers. DICK'S and NIKE customers can now connect their DICK'S Scorecard and NIKE Membership accounts through the DICK'S mobile app. DICK'S and NIKE aim to make the experience simple and convenient by providing an easy-to-use platform where customers can seamlessly shop an expanded selection of NIKE footwear and apparel. As part of this collaboration, DICK'S and NIKE will continually work together across their respective physical and digital properties to deliver enhanced convenience, new experiences and content for customers and better anticipate and fulfill their evolving needs.

07:05 EDT Norwegian Cruise Line reports Q3 monthly average cash burn $275M - The Company continues to take proactive measures to enhance liquidity and financial flexibility in the current environment. As of September 30, 2021, the Company's total debt position was $12.4 billion and the Company's cash and cash equivalents were $1.9 billion. The Company has taken the following additional actions to enhance its liquidity profile and financial flexibility since June 30, 2021: In November 2021, the Company entered into a $1 billion commitment through August 15, 2022 that provides additional liquidity to the Company. If drawn, this commitment will convert into an unsecured note maturing in April 2024. The Company has not drawn and currently does not intend to draw under this commitment. Diversified its credit card processors with the addition of Worldpay from FIS(R) as a preferred payments processor globally. In July 2021, the Company amended nine credit facilities for newbuild agreements and increased the combined commitments under such credit facilities by approximately $770 million to cover owner's supply. modifications and financing premiums. The Company's monthly average cash burn for the third quarter 2021 was approximately $275 million, below prior guidance of approximately $285 million. Looking ahead, the Company expects fourth quarter 2021 monthly average cash burn to increase to approximately $350 million driven by the continued phased relaunch of additional vessels. This cash burn rate does not include expected cash inflows from new and existing bookings or contribution from ships that have re-entered service. Cash burn rates include ongoing ship operating expenses, administrative operating expenses, interest expense, taxes, debt deferral fees and expected non-newbuild capital expenditures and exclude cash refunds of customer deposits as well as cash inflows from new and existing bookings, newbuild related capital expenditures and other working capital changes. Future cash burn rate estimates also exclude unforeseen expenses. The third quarter 2021 cash burn rate and fourth quarter estimate also reflect the deferral of debt amortization and newbuild related payments.

07:04 EDT Norwegian says net bookings have materially improved over past six weeks - Net booking volumes in the third quarter 2021 were negatively impacted by the Delta variant. The resulting slowdown in net booking volumes was heavily weighted to sailings in the fourth quarter of 2021 and early 2022 and improved sequentially through 2022. The impact has since abated and net bookings have materially improved over the past six weeks with particular strength for bookings related to sailings in the second half of 2022 and into 2023. Despite the temporary Delta impact, the Company's overall cumulative booked position for full year 2022 is in line with 2019's record levels at higher pricing even when including the dilutive impact of future cruise credits ("FCCs"). The overall cumulative booked position for the second half of 2022, when the full fleet is expected to be back in operation and at normalized occupancy levels, is meaningfully higher than 2019 and at higher prices. The Company's advance ticket sales were $1.7 billion, including the long-term portion, which includes approximately $750 million of FCCs as of September 30, 2021. Advance ticket sales increased $0.3 billion on a net basis from the end of the second quarter even with approximately $100 million of revenue recognized in the quarter.

07:02 EDT Marriott reports Q3 comparable systemwide constant dollar RevPAR down 25.8% - Third quarter 2021 comparable systemwide constant dollar RevPAR declined 25.8% worldwide, 19.9% in the U.S. & Canada, and 40.7% in international markets, compared to the 2019 third quarter. Third quarter 2021 comparable systemwide constant dollar RevPAR increased 118.4% worldwide, 134.7% in the U.S. & Canada, and 76.3% in international markets, compared to the 2020 third quarter.

06:58 EDT R.R. Donnelley to be acquired by Atlas for $8.52 per share in cash - R.R. Donnelley & Sons Company announced that it has entered into a definitive merger agreement to be acquired by affiliates of Atlas Holdings LLC, which operates a global family of manufacturing and distribution businesses, in an all-cash transaction with a total enterprise value of approximately $2.1 billion. The merger agreement has been unanimously approved by RRD's board of directors. Under the terms of the merger agreement, Atlas will acquire all of the outstanding shares of RRD common stock, and RRD stockholders will receive $8.52 per share in cash for each share of RRD common stock. The purchase price represents a premium of approximately 29.1 percent over RRD's closing price on November 2, 2021, approximately 72.8 percent over RRD's closing share price on October 11, 2021, the last trading day prior to the announcement of a non-binding offer by Chatham Asset Management, LLC, and a premium of approximately 64.1 percent over RRD's 60-day volume weighted average price for the period ended October 11, 2021. "The RRD board regularly reviews the Company's strategic priorities, and today's announcement is a culmination of a thorough, multi-year process to maximize value for RRD stockholders," said John Pope, RRD Chairman of the Board of Directors. "After a careful and thorough analysis, the RRD board believes that this transaction, which delivers an immediate premium and certain cash value, is in the best interest of RRD and our stockholders. We look forward to working with Atlas to complete this value enhancing transaction." Atlas intends to finance the transaction through a combination of committed equity financing provided by affiliates of Atlas as well as debt financing that has been committed to by JPMorgan Chase Bank, N.A. and Macquarie Capital. The transaction is not subject to a financing condition. Under the terms of the merger agreement, RRD may solicit additional acquisition proposals from third parties for a period of 25 calendar days from the signing of the merger agreement.

06:49 EDT Coterra Energy sees Q4 total equivalent production 665-690 MBoepd - The company said, "The Company is providing fourth-quarter 2021 guidance which fully incorporates legacy Cimarex operations. Coterra expects fourth-quarter 2021 total equivalent production to average 665 to 690 MBoepd. Gas production for the total company is expected to average between 3,060 and 3,150 MMcfpd. Oil production is expected to average 86 to 90 MBopd, the midpoint representing 30 percent year-over-year growth from legacy Cimarex's fourth-quarter 2020 oil production of 67.8 MBopd. Coterra is currently running five rigs and two completion crews in the Permian Basin and two rigs and two completion crews in the Marcellus Shale. Coterra plans to average four completion crews during the fourth quarter of 2021, and expects to incur between $245 and $275 million of capital expenditures."

06:43 EDT Babcock & Wilcox's Environmental segment awarded $5M contract in Middle East - Babcock & Wilcox's B&W Environmental segment has been awarded a contract for approximately $5M to supply a SPIG S.p.A. cooling system for a petrochemical facility in the Middle East. The cooling tower will be used to provide cooling for propane dehydrogenation and polypropylene production equipment while reducing environmental impact by conserving water and reducing liquid discharge.

06:24 EDT SiteOne Landscape raises 2021 adjusted EBITDA view to $380M-$400M - Previous view for 2021 adjusted EBITDA was $335M-$365M.

06:21 EDT CDC recommends Pfizer's Covid-19 vaccine for children 5-11 years - CDC Director Rochelle P. Walensky, M.D., M.P.H., on Tuesday night endorsed the CDC Advisory Committee on Immunization Practices' recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer (PFE)-BioNTech (BNTX) pediatric vaccine. CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible, it said in a statement. Walensky said: "Together, with science leading the charge, we have taken another important step forward in our nation's fight against the virus that causes COVID-19. We know millions of parents are eager to get their children vaccinated and with this decision, we now have recommended that about 28 million children receive a COVID-19 vaccine. As a mom, I encourage parents with questions to talk to their pediatrician, school nurse or local pharmacist to learn more about the vaccine and the importance of getting their children vaccinated." Reference Link

06:10 EDT John Deere UAW members stay on strike - By a vote of 45% yes to 55% no, UAW John Deere members voted down the agreement this evening, the union said in a statement. The UAW said: "The strike against John Deere and Company will continue as we discuss next steps with the company. Pickets will continue and any updates will be provided through the local union." Reference Link

06:03 EDT Amazon.com launches 'FamilyFlex' benefits program - Amazon announced the launch of Amazon FamilyFlex, a program that provides new and current employees flexibility and expansive benefits for themselves and their families. Amazon FamilyFlex gives employees, which may differ by business and employment type, the resources to create the right balance between home life and work life, including pregnancy and parental leave, adoption assistance, and in select roles, the ability to swap shifts and create custom schedules. The program is a result of feedback from employees on the most effective ways to provide flexibility and support in managing their work and personal lives.

05:29 EDT iRhythm comments on CMS MPFS Final Rule - iRhythm commented on the Centers for Medicare and Medicaid Services, or CMS, Calendar Year 2022 Medicare Physician Fee Schedule, or MPFS, Final Rule. The Final Rule and accompanying Addenda were released on November 2, along with updated payment policies, payment rates, and other provisions for services furnished under MPFS on or after January 1, 2022. In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the company's Zio XT service. iRhythm and other industry participants have been working with Medicare Administrative Contractors, or MACs, to establish pricing for these codes. iRhythm remains engaged with all of the MACs and is working with other industry participants to submit additional cost data on long-term continuous ECG monitoring for consideration to establish fair and appropriate local rates. iRhythm is evaluating the new information included in the Final Rule and its potential implications on discussions with the MACs. iRhythm cannot provide certainty at this time on the potential outcome of the discussions with the MACs or on the timing of any action to be taken."While we are disappointed that national pricing was not included in the 2022 physician fee schedule, we are appreciative that CMS continues to engage with industry and other stakeholders to further their understanding of the cost components of AI-based solutions such as iRhythm's Zio service. We firmly believe that national pricing remains the best option for all stakeholders," said Quentin Blackford, iRhythm President and CEO. "In the meantime, we will continue to work with the MACs to provide information for the Calendar Year 2022 rate setting process and believe the Final Rule is potentially constructive in our conversations with the MACs. We will share updates at the appropriate time."

05:23 EDT Chatham increases offer to acquire R.R. Donnelley to $9.00-$9.50 per share - Chatham Asset Management, a private investment firm which manages funds that beneficially own approximately 14.9% of the outstanding common stock of R.R. Donnelley and which is the largest bondholder of the company, in a letter sent to RRD's board of directors, submitted an enhanced offer to acquire all the common stock of RRD not already owned by Chatham for $9.00-$9.50 per share in cash. The offer is subject to RRD enabling Chatham to conduct appropriate due diligence. The letter said, "On October 12, 2021, Chatham Asset Management, LLC (together with its affiliates, "we" or "Chatham"), the largest stockholder and debtholder of R.R. Donnelley & Sons Company ("RRD" or the "Company"), submitted a non-binding proposal to acquire all of the common stock of RRD not already owned by Chatham at a price equal to $7.50 per share (the "Original Offer"). Our Original Offer not only included a highly confident letter from Jefferies Group LLC supporting our ability to finance the transaction, but also contemplated a plan to equitize and/or subordinate our debt position which would significantly deleverage the Company. Since we submitted our Original Offer, we have expended significant time and resources trying to execute a non-disclosure agreement to begin discussions with the Company regarding our offer. We also have increased our ownership of the Company's outstanding debt, to an aggregate of approximately $654.4 million, as further evidence of our commitment to achieving a successful and value-maximizing transaction. Despite these efforts, the Board refused to engage with us. We now have learned, through a leaked story to the Wall Street Journal, that RRD is prepared to announce a definitive agreement with Atlas Holdings ("Atlas") later this morning, whereby Atlas will acquire RRD's outstanding stock for $8.50 per share. The Board's decision to sign a definitive agreement with Atlas, that may include a substantial break-up fee, without any conversation with us regarding our Original Offer raises major concerns. We question how the Board could have undertaken a credible and fulsome strategic review process without any discussion or evaluation of our offer. While we remain deeply troubled by the Board's conduct to date, we remain committed to acquiring RRD and are prepared to increase our offer to $9.00 to $9.50 per share in cash if we can immediately execute a confidentiality agreement, conduct appropriate due diligence, and commence good faith negotiations with the Company. We urge the Board to fulfill its fiduciary obligations and immediately reengage with us so that RRD stockholders can receive superior value for their shares. Short of that, we must reserve all rights to protect our investment."

05:17 EDT Cedar Fair reports preliminary October revenue $219M, up 42% vs. 2019 - For the five-week period ended October 31, preliminary net revenues totaled $219M, representing an increase of 42%, or $65M, from the comparable five-week period in 2019. The increase was driven by an 8% increase in attendance to 3.2M total visits; a 32% increase in in-park per capita spending to a record $64.86; and a 33% increase in out-of-park revenues to $19M.

05:06 EDT Volvo Autonomous Solutions, Holcim partner to test autonomous electric haulers - Volvo Autonomous Solutions and Holcim Switzerland have partnered to jointly test and further develop the use of autonomous electric haulers in a limestone quarry. The two companies are dedicated to seeking infrastructure and transport solutions that are safe, efficient, innovative and sustainable. Volvo Autonomous Solutions and Holcim Switzerland have entered a collaboration to jointly test and further develop the use of autonomous electric haulers in a limestone quarry. Holcim's quarry Gabenchopf in Siggenthal has been chosen as the site for this project.